Palmitoylation of the V-2 vasopressin receptor

被引:61
|
作者
Sadeghi, HM
Innamorati, G
Dagarag, M
Birnbaumer, M
机构
[1] UNIV CALIF LOS ANGELES, SCH MED, DEPT ANESTHESIOL, LOS ANGELES, CA 90095 USA
[2] UNIV CALIF LOS ANGELES, SCH MED, INST MOL BIOL, LOS ANGELES, CA 90095 USA
关键词
D O I
10.1124/mol.52.1.21
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Palmitoylation of the V-2 vasopressin receptor (V2R) and its functional role were investigated in transfected cells. Palmitoylation was assessed by incubating transfected cells with [H-3]palmitic acid and immunoprecipitating the receptor with an antibody raised against a portion of the third intracellular loop of V2R. Wild-type and nonglycosylated V2R yielded tritium signals at 45-55 and 40 kDa, respectively, demonstrating that the V2R is palmitoylated and that receptor palmitoylation is independent of glycosylation. Substitution of CC341/342 for serines eliminated receptor palmitoylation, whereas replacement of a single amino acid, C341S or C342S, restored partial palmitoylation. Saturation binding assays revealed decreased cell surface expression of the nonpalmitoylated receptor compared with the wild-type; this effect was more pronounced when a truncated form of V2R (G345ter) was studied. The presence of either cysteine residue (C341S or C342S) elevated receptor expression to normal levels, most likely due to the partial restoration of palmitoylation. Ligand binding affinity, hormone-induced stimulation of adenylyl cyclase activity, receptor internalization, and desensitization were not affected by the absence of palmitoylation. No increase but rather a slight decrease in the extent of receptor palmitoylation was detected after exposure to vasopressin. It was concluded that the V2R is palmitoylated in both cysteines, each cysteine is palmitoylated independently from the other, and palmitoylation enhances cell surface expression of the V2R.
引用
收藏
页码:21 / 29
页数:9
相关论文
共 50 条
  • [21] Recent advances in the discovery and development of vasopressin antagonists: Peptide and nonpeptide V-1a and V-2 receptor antagonists
    Albright, JD
    Chan, PS
    [J]. CURRENT PHARMACEUTICAL DESIGN, 1997, 3 (06) : 615 - 632
  • [22] AN EXTRACELLULAR RESIDUE DETERMINES THE AGONIST SPECIFICITY OF V-2 VASOPRESSIN RECEPTORS
    UFER, E
    POSTINA, R
    GORBULEV, V
    FAHRENHOLZ, F
    [J]. FEBS LETTERS, 1995, 362 (01) : 19 - 23
  • [23] Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V-2 receptor antagonist
    SerradeilLeGal, C
    Lacour, C
    Valette, G
    Garcia, G
    Foulon, L
    Galindo, G
    Bankir, L
    Pouzet, B
    Guillon, G
    Barberis, C
    Chicot, D
    Jard, S
    Vilain, P
    Garcia, C
    Marty, E
    Raufaste, D
    Brossard, G
    Nisato, D
    Maffrand, JP
    LeFur, G
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (12): : 2729 - 2738
  • [24] V-2
    Gardner, Thomas S.
    [J]. SCIENTIFIC MONTHLY, 1955, 80 : 61 - 61
  • [25] DISTRIBUTION AND DEVELOPMENTAL-CHANGES IN VASOPRESSIN V-2 RECEPTOR MESSENGER-RNA IN RAT-BRAIN
    KATO, Y
    IGARASHI, N
    HIRASAWA, A
    TSUJIMOTO, G
    KOBAYASHI, M
    [J]. DIFFERENTIATION, 1995, 59 (03) : 163 - 169
  • [26] LATERAL MOBILITY OF THE ANTAGONIST-OCCUPIED V-2 VASOPRESSIN RECEPTOR IN MEMBRANES OF RENAL EPITHELIAL-CELLS
    PAVO, I
    JANS, DA
    PETERS, R
    PENKE, B
    FAHRENHOLZ, F
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1994, 1223 (02): : 240 - 246
  • [27] Effects of CL-385004, a nonpeptidic vasopressin V-1a/V-2 receptor antagonist, in a rat model of heart failure
    Hartupee, DA
    Coupet, J
    Venkatesan, AM
    Cervoni, P
    Spinelli, W
    Park, S
    Radin, MJJ
    McCune, SA
    [J]. CIRCULATION, 1997, 96 (08) : 3416 - 3416
  • [28] NOVEL LINEAR ANTAGONISTS OF THE ANTIDIURETIC (V-2) AND VASOPRESSOR (V-1) RESPONSES TO VASOPRESSIN
    MANNING, M
    KLIS, WA
    KRUSZYNSKI, M
    PRZYBYLSKI, JP
    OLMA, A
    WO, NC
    PELTON, GH
    SAWYER, WH
    [J]. INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, 1988, 32 (06): : 455 - 467
  • [29] Pharmacological profile of YMO87, a novel nonpeptide dual vasopressin V-1A and V-2 receptor antagonist, in dogs
    Yatsu, T
    Tomura, Y
    Tahara, A
    Wada, K
    Tsukada, J
    Uchida, W
    Tanaka, A
    Takenaka, T
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 321 (02) : 225 - 230
  • [30] Forskolin stimulates cAMP production by stimulating vasopressin V-2 receptors.
    Ning, XP
    Lock, YW
    Tanikella, TK
    Park, CH
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A0109 - A0109